EXELIXIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.12 USD | +0.62% |
|
-2.18% | -11.96% |
| 14/05 | Stephens Initiates Exelixis With Equalweight Rating, $23 Price Target | MT |
| 10/05 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EXELIXIS, INC. | Bio Therapeutic Drugs | +0.62% | -2.18% | -11.96% | +8.31% | +9.26% | 6.11B |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- EXEL Stock
- Charts Exelixis, Inc.
- Comparison Chart